16 research outputs found
Two-year efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: the MOBILE study
Contextual Object Detection with a Few Relevant Neighbors
A natural way to improve the detection of objects is to consider the
contextual constraints imposed by the detection of additional objects in a
given scene. In this work, we exploit the spatial relations between objects in
order to improve detection capacity, as well as analyze various properties of
the contextual object detection problem. To precisely calculate context-based
probabilities of objects, we developed a model that examines the interactions
between objects in an exact probabilistic setting, in contrast to previous
methods that typically utilize approximations based on pairwise interactions.
Such a scheme is facilitated by the realistic assumption that the existence of
an object in any given location is influenced by only few informative locations
in space. Based on this assumption, we suggest a method for identifying these
relevant locations and integrating them into a mostly exact calculation of
probability based on their raw detector responses. This scheme is shown to
improve detection results and provides unique insights about the process of
contextual inference for object detection. We show that it is generally
difficult to learn that a particular object reduces the probability of another,
and that in cases when the context and detector strongly disagree this learning
becomes virtually impossible for the purposes of improving the results of an
object detector. Finally, we demonstrate improved detection results through use
of our approach as applied to the PASCAL VOC and COCO datasets
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Supported by F. Hoffmann–La Roche
Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate is similar in postmenopausal osteoporosis: 1-year results from MOBILE
Once-monthly and daily oral ibandronate are at least as effective in improving proximal femur BMD in postmenopausal osteoporosis: 12-month data from MOBILE
Once-monthly oral ibandronate (Boniva) dosing is highly efficacious in postmenopausal osteoporosis: 2-year results from MOBILE
peer reviewe
Once-monthly dosing of oral ibandronate is highly efficacious: 2-year results from mobile
peer reviewe
Monthly oral ibandronate is at least as effective as daily oral ibandronate: 1-year results from MOBILE
Once-monthly dosing of oral ibandronate is at least as effective as daily dosing in postmenopausal osteoporosis : 1-year results from mobile
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled study
Summary In this 2-year extension of a 3-year study, bazedoxifene showed sustained efficacy in preventing new vertebral fractures in postmenopausal women with osteoporosis and in preventing non-vertebral fractures in higherrisk women. Bazedoxifene significantly increased bone mineral density and reduced bone turnover versus placebo and was generally safe and well tolerated. Introduction This study evaluated the efficacy and safety of bazedoxifene for the treatment of postmenopausal osteoporosis over 5 years. Methods A total of 4,216 postmenopausal women with osteoporosis were enrolled in this 2-year extension of a 3-year, randomized, double-blind, placebo-controlled, phase 3 trial. In the core study (N=7,492), subjects received bazedoxifene 20 or 40 mg/day, raloxifene 60 mg/day, or placebo. The raloxifene arm was discontinued after 3 years; subjects receiving bazedoxifene 40 mg were transitioned to bazedoxifene 20 mg after 4 years. Five-year findings are reported for bazedoxifene 20 and 40/20 mg and placebo. Endpoints included incidence of new vertebral fractures (primary) and non-vertebral fractures, and changes in bone mineral density (BMD) and bone turnover markers. Results At 5 years, the incidence of new vertebral fractures in the intent-to-treat population was significantly lower with bazedoxifene 20 mg (4.5%) and 40/20 mg (3.9%) versus placebo (6.8%; P<0.05), with relative risk reductions of 35% and 40%, respectively. Non-vertebral fracture incidence was similar among groups. In a subgroup of higher-risk women (n=1,324; femoral neck T-score ≤-3.0 and/or ≥1 moderate or severe or ≥2 mild vertebral fracture[s]), bazedoxifene 20 mg reduced non-vertebral fracture risk versus placebo (37%; P=0.06); combined data for bazedoxifene 20 and 40/20 mg reached statistical significance (34% reduction; P≤.05). Bazedoxifene significantly increased BMD and reduced bone turnover versus placebo (P≤0.05) and was generally safe and well tolerated. Conclusions The findings support a sustained anti-fracture effect of bazedoxifene on new vertebral fractures in postmenopausal osteoporotic women and on non-vertebral fractures in the higher-risk subgroup of women. © International Osteoporosis Foundation and National Osteoporosis Foundation 2011.link_to_subscribed_fulltex